Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Tobias Engel Ayer BotrelMárcia Datz AbadiLaura Chabrol HaasCássia Rita Pereira da VeigaDominihemberg de Vasconcelos FerreiraDenis Leonardo Fontes JardimPublished in: Journal of medical economics (2021)
At the 12-month landmark, P + A suggests better economic scenario versus N + I as first-line mRCC treatment option for intermediate- and poor-risk groups, through an indirect comparison using sunitinib as a common comparator.